Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the ...

PharmaTher Holdings (CSE:PHRM) is on track to resubmit information to the U.S. Food and Drug Administration (FDA) by the end ...

Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com. 3 Colijn JM, Liefers B ...

At the University of Oklahoma, Prof. Indrajeet Sharma is leading a team of scientists that is working on a ‘skeletal editing’ ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company’s investigational UKidney™ derived from a 10 gene-edited source pig. The study will ...

Prince Harry has lived in the US for over four years, but many questions have been raised as to the validity of his visa due ...

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC and CBG.

Eton Pharmaceuticals, Inc. announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025, allowing the agency additional time to review ...

In September of 2023 Vanda submitted a New Drug Application (NDA) seeking approval by the FDA. In September of 2024 the FDA rejected the application via a Complete Response Letter, suggesting that ...